Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Pengana’s James McDonald is tipping into Aussie names Telix and Opthea, potash producer K+S, and the valuation case for Ardent at 70¢. The Carlyle Group and its newly acquired life sciences arm ...

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating ...

Bell Potter analyst Thomas Wakim maintained a Buy rating on Opthea Limited (CKDXF – Research Report) today and set a price target of A$1.30.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET ...

Our latest round-up of biotech financings includes nine-figure rounds for Marea, Santa Ana Bio, and Opthea, with InduPro, Elion, and iOnctura also in on the action. Incubated by Third Rock ...

Opthea overhauls leadership. Australia and US-based Opthea, a clinical-stage biopharmaceutical company developing a novel therapy for wet AMD, announced a number of key appointments: Biotechs hire ...